Bolsa, mercados y cotizaciones

COMUNICADO: La Comisión Europea aprueba las nuevas instrucciones de almacenamiento para BYETTA(R) (y 2)



    [TAB]

    REFERENCIAS

    (1) The European Public Assessment Report for Byetta. Disponible en

    http://www.emea.europa.eu/humandocs/Humans/EPAR/byetta/byetta.htm.

    Acceso desde el 5 de julio de 2007.

    (2) Barnett AH, Trautmann M, Burger J, Johns D, Kim D, Brodows R, Festa

    A, Roberts A. A comparison of exenatide and insulin glargine in

    patients using a single oral antidiabetic agent. Datos presentados

    en la 42 Reunión Anual de la European Association of the Study of

    Diabetes. 16 de septirmbre de 2006.

    (3) Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG.

    Exenatide versus insulin glargine in patients withsuboptimally

    controlled type 2 diabetes: A randomized trial. Annals of Internal

    Medicine 2005; 143(8):559-69.

    (4) Nauck MA, Duran S, Kim D, Johns D, Northrup J, Festa A, Brodows B,

    Trautmann M. A comparison of twice-daily exenatide and biphasic

    insulin aspart in patients with type 2 diabetes who were

    suboptimally controlled with sulfonylurea and metformin: A

    noninferiority study. Diabetologia 2007; 50:259-267

    (5) Trautmann ME., Burger J., Johns D., Brodows R., Okerson T., Roberts

    A., and Barnett A. Less hypoglycemia with exenatide versus insulin

    glargine, despite similar HbA1c improvement, in patients with T2DM

    adjunctively treated with metformin. Datos presentados en las 67

    Sesiones Científicas de la American Diabetes Association, 24 de

    junio de 2007, Abstract # 0172-OR.

    (6) The International Diabetes Federation Diabetes Atlas. Disponible en:

    http://www.idf.org/home/index.cfm?unode=3B96906B-C026-2FD3-

    87B73F80BC22682A. Accesible desde el 14 de junio de 2007.

    (7) The International Diabetes Federation, Prevalence / All diabetes.

    Disponible en http://www.eatlas.idf.org/Prevalence/All_diabetes/.

    (8) Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet,

    sulfonylurea, metformin, or insulin in patients with type 2 diabetes

    mellitus: progressive requirement for multiple therapies (UKPDS 49).

    JAMA 1999; 281(21):2005-2012.

    (9) The International Diabetes Federation, Complications. Disponible en

    http://www.eatlas.idf.org/Complications/

    (10) The International Diabetes Federation, Diabetes Atlas, Second

    edition. The Economic Impact of Diabetes. 2003:186.

    [FTAB]

    (Logo: http://www.newscom.com/cgi-bin/prnh/20040122/LILLYAMYLINLOGO )

    Medios, Derin Denham de Eli Lilly and Company, +1-317-277-6749, o móvil, +1-317-370-1435; o Alice Bahner Izzo de Amylin, +1-858-642-7272, o móvil, +1-858-232-9072. Foto: http://www.newscom.com/cgi-bin/prnh/20040122/LILLYAMYLINLOGO , PRN Photo Desk, photodesk@prnewswire.com